Back to top

Press Releases

The Zacks Analyst Blog Highlights: Total System Services, Bank of America, The Royal Bank of Scotland Group, BancorpSouth and Pfizer

TSS BAC RBS BXS PFE

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

For Immediate Release

Chicago, IL – July 23, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Total System Services, Inc. (TSS - Analyst Report), Bank of America Corporation (BAC - Analyst Report), The Royal Bank of Scotland Group plc (RBS - Snapshot Report), BancorpSouth, Inc. (BXS - Analyst Report) and Pfizer Inc. (PFE - Analyst Report).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Friday’s Analyst Blog:

 

Total System Extends BofA Ties

In a bid to further consolidate its year-long business ties, Total System Services, Inc. (TSS - Analyst Report) has entered into an agreement with Bank of America Corporation (BAC - Analyst Report) to provide its consumers processing services related to its credit card portfolio in the U.S. While most of the provisions remain undisclosed, it has been announced that the tenure of the services will be at least six years.

 

The company also declared that it expects to conclude the conversion of Bank of America’s consumer card portfolio from its in-house processing system by June 2014. The agreement allows Bank of America to use the TS2 software, the payment for which will be met over the long term.

 

Per the agreement, Bank of America will have access to Total System’s core payments engine, TS2, together with the right to use various customized processing solutions.  The utilization of these services under the guidance of skilled personnel will ensure the smooth address of issues related to risk and financial management and will be beneficial to Bank of America.

 

The new agreement is in furtherance of a previous accord between the companies, under which, Total System processed small and other commercial business cards of Bank of America on its TS2 platform. In 2010, Bank of America extended its long-term contract for merchant and other card processing services through a new joint venture.

 

Overall, Total System’s contract portfolio received a boost in 2012 when it attained processing contracts from renowned banks like Royal Bank of Scotland, a unit of The Royal Bank of Scotland Group plc (RBS - Snapshot Report), BancorpSouth, a unit of BancorpSouth, Inc. (BXS - Analyst Report) and other banks of such stature. 

 

Total System is scheduled to release its second quarter results after the closing bell on July 24. The Zacks Consensus Estimate for earnings for the quarter is currently pegged at 32 cents per share, representing an estimated year-over-year increase of 13.1%.

The company currently retains a Zacks #2 Rank, which translates into a short-term Buy rating. We maintain a long-term Neutral recommendation on the stock.



Lyrica Court Win for Pfizer

Pfizer Inc. (PFE - Analyst Report) recently received good news with the United States District Court for the District of Delaware upholding the company’s patent for Lyrica. Lyrica is approved for several indications including the management of post-herpetic neuralgia, diabetic peripheral neuropathy and fibromyalgia.

 

The Court upheld the composition of matter patent and pain and seizure use patents. Based on this favorable decision, Lyrica should be protected from genericization through December 30, 2018 in the US, unless the generic challengers file and win an appeal.

 

Lyrica accounts for a major part of Pfizer’s revenues with 2011 sales coming in at $3.7 billion. The product continues to perform well and we believe Lyrica has the most potential within Pfizer’s current product suite. It has experienced a very strong ramp since its introduction and we expect the strong growth to continue with label expansions.

 

 

 

 Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.

 

 

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.77 +6.05%
SKECHERS USA SKX 38.53 +4.50%
QUESTCOR PHA QCOR 80.07 +2.47%
VIPSHOP HOLD VIPS 156.35 +1.82%
ENLINK MIDS ENLC 36.29 +1.60%